All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 145 points (-0.8%) at 17,585 as of Tuesday, Dec. 8, 2015, 11:55 AM ET. The NYSE advances/declines ratio sits at 885 issues advancing vs. 2,088 declining with 150 unchanged.

The Health Care sector currently sits up 0.4% versus the S&P 500, which is down 0.6%. Top gainers within the sector include TherapeuticsMD ( TXMD), up 38.4%, Celgene ( CELG), up 2.4%, Biogen ( BIIB), up 1.5%, Bristol-Myers Squibb Company ( BMY), up 0.7% and Amgen ( AMGN), up 0.7%. On the negative front, top decliners within the sector include Mallinckrodt ( MNK), down 6.1%, Dr Reddy Laboratories ( RDY), down 5.1%, Shire ( SHPG), down 1.9%, AstraZeneca ( AZN), down 1.6% and Sanofi ( SNY), down 1.5%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3. Illumina ( ILMN) is one of the companies pushing the Health Care sector higher today. As of noon trading, Illumina is up $2.46 (1.4%) to $178.55 on light volume. Thus far, 534,480 shares of Illumina exchanged hands as compared to its average daily volume of 2.5 million shares. The stock has ranged in price between $173.56-$180.48 after having opened the day at $175.15 as compared to the previous trading day's close of $176.09.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Illumina, Inc. provides sequencing and array-based solutions for genetic analysis in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $26.2 billion and is part of the drugs industry. Shares are down 4.6% year-to-date as of the close of trading on Monday. Currently there are 10 analysts who rate Illumina a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Illumina as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year. Get the full Illumina Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Regeneron Pharmaceuticals ( REGN) is up $4.86 (0.9%) to $551.47 on light volume. Thus far, 150,387 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 874,500 shares. The stock has ranged in price between $540.00-$554.16 after having opened the day at $542.87 as compared to the previous trading day's close of $546.61.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Regeneron Pharmaceuticals has a market cap of $57.1 billion and is part of the drugs industry. Shares are up 33.2% year-to-date as of the close of trading on Monday. Currently there are 9 analysts who rate Regeneron Pharmaceuticals a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, compelling growth in net income, good cash flow from operations and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Regeneron Pharmaceuticals Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Eli Lilly and ( LLY) is up $0.69 (0.8%) to $87.07 on average volume. Thus far, 2.2 million shares of Eli Lilly and exchanged hands as compared to its average daily volume of 5.6 million shares. The stock has ranged in price between $85.56-$87.67 after having opened the day at $85.74 as compared to the previous trading day's close of $86.38.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. Eli Lilly and has a market cap of $96.0 billion and is part of the drugs industry. Shares are up 25.2% year-to-date as of the close of trading on Monday. Currently there are 8 analysts who rate Eli Lilly and a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Eli Lilly and as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, expanding profit margins and notable return on equity. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full Eli Lilly and Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).